Primecap Management Co. CA Buys New Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Primecap Management acquired 3.41 million Edwards Lifesciences shares in the second quarter, valued at approximately $308.3 million and representing about 0.59% of the company. Institutional investors collectively own 79.46% of EW.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 EPS versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. The company guided for third-quarter 2026 EPS of $0.71–$0.77 and full-year EPS of $2.95–$3.05.
• Analysts maintain a generally positive view, with 17 Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $100.27, above the reported share price of $90.92.

Primecap Management Co. CA acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,408,291 shares of the medical research company's stock, valued at approximately $308,314,000. Primecap Management Co. CA owned approximately 0.59% of Edwards Lifesciences as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $266,000. NewEdge Advisors LLC boosted its stake in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock worth $2,787,000 after purchasing an additional 2,665 shares in the last quarter. Sei Investments Co. boosted its stake in Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock worth $32,285,000 after purchasing an additional 58,988 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after purchasing an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $90.92 on Wednesday. The firm's 50 day simple moving average is $89.35 and its 200 day simple moving average is $84.82. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a market capitalization of $52.35 billion, a price-to-earnings ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 EPS. Edwards Lifesciences's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on EW. Mizuho upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Evercore restated an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. BTIG Research boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source